Trial Profile
A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients With a History of Frequent Acute Exacerbations While on Maintenance Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs AZD 7624 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 24 May 2017 Results evaluating exacerbation based composite endpoint (ExDO), presented at the 113th International Conference of the American Thoracic Society.
- 24 May 2017 Primary endpoint (Time to first moderate to severe COPD exacerbation or discontinuation) has not been met as per the results presented at the 113th International Conference of the American Thoracic Society
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society